文献速递浆细胞疾病

达雷妥尤单抗、卡非佐米、来那度胺和地塞米松治疗新诊断多发性骨髓瘤的MRD驱动2期研究

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.
PubMed 文献 · Blood Adv · 2025-01-01

该2期试验评估Dara-KRd诱导后基于二代测序的MRD适应策略治疗新诊断多发性骨髓瘤,39例中诱导后≥CR率54%(P=.375),主要终点未达到,但≥CR和MRD阴性率高且无新安全性问题,MRD适应策略使MRD阳性患者反应加深、MRD阴性患者维持持久MRD控制。

要点

  • 39例新诊断多发性骨髓瘤患者接受Dara-KRd诱导,诱导后≥CR率为54%(21/39),主要终点未达到(P=.375)。
  • 诱导后MRD阴性率10^-5为59%、10^-6为41%;MRD阴性组(n=24)来那度胺维持,18例中14例(77.8%)持续MRD阴性≥12周期。
  • MRD阳性可移植组(n=8)自体干细胞移植后62.5%转为10^-5 MRD阴性(10^-6为37.5%),MRD阳性不可移植组(n=4)KRd巩固后最佳MRD阴性率提升至77%(10^-5)和72%(10^-6)。

核心结论

  • 主要终点未达到,但Dara-KRd诱导在新诊断多发性骨髓瘤中取得高≥CR率和MRD阴性率,且无新安全性问题。
  • 诱导后MRD适应策略使MRD阳性患者反应加深,并使MRD阴性患者维持持久MRD控制。

研究设计与样本

  • 2期试验,评估达雷妥尤单抗、卡非佐米、来那度胺和地塞米松(Dara-KRd)诱导后基于二代测序的MRD适应策略。
  • 共39例新诊断多发性骨髓瘤患者;主要终点为诱导后完全缓解(CR)和严格完全缓解(≥CR)。
  • 采用流式细胞术分析T细胞;试验注册号NCT04113018。

主要发现

  • 39例中21例(54%)诱导后达到≥CR(P=.375),MRD阴性率10^-5为59%、10^-6为41%。
  • MRD阴性组(A组,n=24)接受来那度胺维持,18例中14例(77.8%)持续MRD阴性≥12周期。
  • MRD阳性可移植组(B组,n=8)接受自体干细胞移植,移植后62.5%转为10^-5 MRD阴性(10^-6为37.5%)。
  • MRD阳性不可移植组(C组,n=4)接受KRd巩固,最佳MRD阴性率提升至77%(10^-5)和72%(10^-6)。
  • 中位随访30.1个月,A、B、C组分别有3、2、1例患者进展或死亡;Dara-KRd未发现新安全性问题。

关键数值与推荐

  • 诱导后≥CR率为54%(21/39,P=.375)。
  • 诱导后MRD阴性率10^-5为59%、10^-6为41%。
  • A组18例中14例(77.8%)持续MRD阴性≥12周期。
  • B组移植后10^-5 MRD阴性转化率62.5%,10^-6为37.5%。
  • C组最佳MRD阴性率10^-5为77%、10^-6为72%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 主要终点未达到(P=.375)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In newly diagnosed multiple myeloma (NDMM), measurable residual disease (MRD) status is prognostically important, but its role in treatment decisions remains unclear. In a phase 2 trial, we assessed daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) induction followed by a next-generation sequencing-based MRD-adapted strategy. The primary outcome was complete response (CR) and stringent CR (≥CR) after induction. Flow cytometry was used to profile T cells. Among 39 patients, 21 (54%) achieved ≥CR after induction (P = .375), with MRD-negative rates of 59% (10-5) and 41% (10-6). Patients who were MRD-negative (n = 24, group A) received lenalidomide maintenance, showing sustained MRD negativity in 14 of 18 (77.8%) for ≥12 cycles. MRD-positive transplant-eligible patients (n = 8, group B) underwent autologous stem cell transplantation, with 62.5% converting to MRD-negative at 10-5 (37.5% at 10-6) posttransplant. MRD-positive, transplant-ineligible patients (n = 4, group C) received KRd consolidation. Best MRD-negative rates improved to 77% (10-5) and 72% (10-6). No new safety concerns were identified for Dara-KRd. With a median follow-up of 30.1 months, 3, 2, and 1 patient(s) in groups A, B, and C, respectively, have progressed or died. We observed that Dara-KRd strongly activated memory T cells, which was associated with an MRD-negative state post induction. Although the primary outcome was not met, Dara-KRd induction in NDMM achieved high ≥CR and MRD-negative rates without new safety concerns. The post induction MRD-adapted strategy deepened responses in MRD-positive patients and maintained durable MRD control in MRD-negative patients. This trial was registered at www.clinicaltrials.gov as #NCT04113018.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bhutani M, Robinson M, Foureau D, et al. MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma. Blood Adv. 2025. PMID: 39576965. doi:10.1182/bloodadvances.2024014417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。